Top

Published in:

01-12-2012 | Research Article

Matrix metalloproteinase 2 polymorphisms and expression in lung cancer: a meta-analysis

Authors: Jiying Wang, Yong Cai

Published in: Tumor Biology | Issue 6/2012

Abstract

A number of studies have investigated the role of matrix metalloproteinase 2 (MMP2) polymorphisms and expression in lung cancer, but have yielded inconsistent and inconclusive results. To derive a more precise estimate of the prognostic role of MMP2 expression and the susceptibility role of MMP2 polymorphisms in lung cancer, we reviewed published studies and carried out a meta-analysis. Eligible articles were identified in electronic databases. Case–control studies assessing the associations between MMP2 polymorphisms and lung cancer risk or cohort studies assessing the prognostic role of MMP2 expression in patients with lung cancer were included. Pooled odds ratio (OR) or hazard ratio (HR) with 95 % confidence interval (95 % CI) was used to assess the role of MMP2 polymorphisms and expression in lung cancer, respectively. Seven case–control studies (a total of 3,190 lung cancer cases and 3,013 controls) and 18 cohort studies (2,095 lung cancer patients) were eligible. Meta-analysis of seven case–control studies suggested that individuals with TT genotype of both MMP2 C735T and C1306T polymorphisms had obviously decreased risk of lung cancer compared with those with CC genotype (for MMP2 C735T, fixed effects OR = 0.69, 95 % CI 0.49–0.97, P = 0.032; for MMP2 C1306T, fixed effects OR = 0.54, 95 % CI 0.33–0.86, P = 0.010). Meta-analysis of 18 cohort studies suggested that patients with high MMP-2 expression had poorer overall survival (fixed effects HR = 1.82, 95 % CI 1.56–2.13, P < 0.001). Subgroup by study design, ethnicity and testing methods all further identified the prognostic value of MMP2 expression in lung cancer. In conclusion, MMP2 C735T and C1306T polymorphisms are both associated with lung cancer risk, and patients with high MMP2 expression levels have poorer overall survival compared with those with low MMP2 expression levels.

Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367–80.PubMedCrossRef

Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, Shepherd FA. Non-small-cell lung cancer. Lancet. 2011;378:1727–40.PubMedCrossRef

Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:379–92.PubMedCrossRef

Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000;18:1135–49.PubMed

Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161–74.PubMedCrossRef

Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol. 2000;19:623.PubMedCrossRef

Price S, Greaves D, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem. 2001;276:7549.PubMedCrossRef

Aysegul B, Veysi GH, Muzaffer M, Irfan D, Azra A, Hulyam K. Is a single nucleotide polymorphism a risk factor for lung cancer in the matrix metalloproteinase-2 promoter? Mol Biol Rep. 2011;38:1469–74.PubMedCrossRef

Rollin J, Regina S, Vourc'h P, Iochmann S, Blechet C, Reverdiau P, Gruel Y. Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer. 2007;56:273–80.PubMedCrossRef

10.

Yu C, Pan K, Xing D, Liang G, Tan W, Zhang L, Lin D. Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res. 2002;62:6430–3.PubMed

11.

Gonzalez-Arriaga P, Pascual T, Garcia-Alvarez A, Fernandez-Somoano A, Lopez-Cima MF, Tardon A. Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer risk and survival. BMC Cancer. 2012;12:121.PubMedCrossRef

12.

Cox G, Jones JL, Andi A, Waller DA, O'Byrne KJ. A biological staging model for operable non-small cell lung cancer. Thorax. 2001;56:561–6.PubMedCrossRef

13.

Matsuo Y, Hashimoto S, Koga T, Yonemitsu Y, Yoshino I, Sugimachi K, Honda H, Masuda K, Sueishi K. Growth pattern correlates with the distribution of basement membrane and prognosis in lung adenocarcinoma. Pathol Res Pract. 2004;200:517–29.PubMedCrossRef

14.

Kodate M, Kasai T, Hashimoto H, Yasumoto K, Iwata Y, Manabe H. Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Pathol Int. 1997;47:461–9.PubMedCrossRef

15.

Yamamura T, Nakanishi K, Hiroi S, Kumaki F, Sato H, Aida S, Kawai T. Expression of membrane-type-1-matrix metalloproteinase and metalloproteinase-2 in nonsmall cell lung carcinomas. Lung Cancer. 2002;35:249–55.PubMedCrossRef

16.

Shou YN, Ping YL, Gong YB, Jia TJ, Ji QH, Dai PD, Chi QJ, Liu DN, Jia TZ. The expression of vegf and MMP-2 in non-small cell lung cancer and their association with pathological factors and prognosis. J China-Japan Friendship Hosp. 2004;8:275–7 [Article in Chinese].

17.

Grossi F, Spizzo R, Bordo D, Cacitti V, Valent F, Rossetto C, Follador A, Di Terlizzi S, Aita M, Morelli A, Fasola G, Consiglieri C, Ceschia T, Beltrami CA, Belvedere O. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014). J Thorac Oncol. 2010;5:1354–60.PubMedCrossRef

18.

Passlick B, Sienel W, Seen-Hibler R, Wockel W, Thetter O, Mutschler W, Pantel K. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res. 2000;6:3944–8.PubMed

19.

Ishikawa S, Takenaka K, Yanagihara K, Miyahara R, Kawano Y, Otake Y, Hasegawa S, Wada H, Tanaka F. Matrix metalloproteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small-cell lung cancer. Clin Cancer Res. 2004;10:6579–85.PubMedCrossRef

20.

Shou Y, Hirano T, Gong Y, Kato Y, Yoshida K, Ohira T, Ikeda N, Konaka C, Ebihara Y, Zhao F, Kato H. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. Br J Cancer. 2001;85:1706–12.PubMedCrossRef

21.

Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.PubMedCrossRef

22.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef

23.

Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.CrossRef

24.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef

25.

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed

26.

Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316:469.PubMedCrossRef

27.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef

28.

Jia SX, Ding CM. Association of single nucleotide polymorphisms in the promoter of MMP-2 and TIMP-2 genes with lung cancer. Wanfang Master Thesis Database. 2009. [Article in Chinese].

29.

Song XY, Li L, Zhang L, Xiong X. Association polymorphisms in the matrix metalloproteinases-2 (MMP-2) gene with non-small cell lung cancer. Sichuan Zhong Liu Fang Zhi. 2007;20:257–9 [Article in Chinese].

30.

Zhou Y, Yu C, Miao X, Wang Y, Tan W, Sun T, Zhang X, Xiong P, Lin D. Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. Carcinogenesis. 2005;26:1117–21.PubMedCrossRef

31.

Wang S, Li B, Li Y, Li J. Expression and clinical significance of CD147 and MMP-2 in squamous cell carcinoma and adenocarcinoma of the lungs. Zhongguo Fei Ai Za Zhi. 2011;14:710–4 [Article in Chinese].PubMed

32.

Zhang HZ, Wei YP, Li HG, Wang M, Liu JG, Wu C. Expressions of vascular endothelial growth factor C and matrix metalloproteinases-2 and prognosis of non-small cell lung carcinoma. Nan Fang Yi Ke Da Xue Xue Bao. 2006;26:1307–10 [Article in Chinese].PubMed

33.

Byun JH, Lee MA, Roh SY, Shim BY, Hong SH, Ko YH, Ko SJ, Woo IS, Kang JH, Hong YS, Lee KS, Lee AW, Park GS, Lee KY. Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer. Jpn J Clin Oncol. 2006;36:263–8.PubMedCrossRef

34.

Shao W, Wang W, Xiong XG, Cao C, Yan TD, Chen G, Chen H, Yin W, Liu J, Gu Y, Mo M, He J. Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage ia non-small cell lung cancer. J Surg Oncol. 2011;104:841–6.PubMedCrossRef

35.

Xue Y, Zhou QH, Zhang SF, Liu LX. A study on the relationship between expression of MMP-2, MMP-9 and metastasis and prognosis in patients with lung cancer. Hua Xi Yi Xue. 2008;23:225–8 [Article in Chinese].

36.

Leinonen T, Pirinen R, Bohm J, Johansson R, Kosma VM. Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. Histol Histopathol. 2008;23:693–700.PubMed

37.

Hoikkala S, Paakko P, Soini Y, Makitaro R, Kinnula V, Turpeenniemi-Hujanen T. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2—complex or TIMP-1 [corrected] in stage [corrected] I–III lung carcinoma. Cancer Lett. 2006;236:125–32.PubMedCrossRef

38.

Zhang HZ, Lu ZQ, Xie DR, Li HG, Xiong LH, Zhang H, Chen XB. Effect of cyclooxygenase-2, and matrix metalloproteinase-2 expression on prognosis of lung cancer. Ai Zheng. 2004;23:1190–3 [Article in Chinese].PubMed

39.

Wong XW, Ren Z, Zhang JH, Liang CZ. Interstitial fibroblasts and tumor cell matrix metalloproteinase-2 expression in non-small cell lung cancer and clinical significance. Shiyong Yi Xue Za Zhi. 2009;25:235-37.

40.

Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D, Kogevinas M, Real FX. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol. 2005;6:678–86.PubMedCrossRef

41.

Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 2004;22:529–36.PubMedCrossRef

42.

Zintzaras E, Lau J. Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol. 2008;61:634–45.PubMedCrossRef

43.

Bonomi P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol. 2002;29:78–86.PubMedCrossRef

44.

Chetty C, Rao JS, Lakka SS. Matrix metalloproteinase pharmacogenomics in non-small-cell lung carcinoma. Pharmacogenomics. 2011;12:535–46.PubMedCrossRef

45.

McColgan P, Sharma P. Polymorphisms of matrix metalloproteinases 1, 2, 3 and 9 and susceptibility to lung, breast and colorectal cancer in over 30,000 subjects. Int J Cancer. 2009;125:1473–8.PubMedCrossRef

46.

Qian Q, Wang Q, Zhan P, Peng L, Wei SZ, Shi Y, Song Y. The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis. Cancer Invest. 2010;28:661–9.PubMedCrossRef

Title: Matrix metalloproteinase 2 polymorphisms and expression in lung cancer: a meta-analysis
Authors: Jiying Wang
Yong Cai
Publication date: 01-12-2012
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 6/2012
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-012-0441-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2012

RHBDD2: a 5-fluorouracil responsive gene overexpressed in the advanced stages of colorectal cancer

The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents

The role of CCND1 alterations during the progression of cutaneous malignant melanoma

Expression of ADAM8 and its clinical values in diagnosis and prognosis of hepatocellular carcinoma

Loss of expression of the differentially expressed in adenocarcinoma of the lung (DAL-1) protein is associated with metastasis of non-small cell lung carcinoma cells

Associations of non-metastatic cells 1 gene polymorphisms with lymph node metastasis risk of gastric cancer in Northern Chinese population

Keynote webinar | Spotlight on antibody–drug conjugates in cancer